A short repost of Eli Lilly trial results, crediting retatrutide with more than twice the weight loss of Ozempic's highest dose.
Recap by typeshit. Post by Facebook on Facebook.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
Speaking on the Q3 2026 earnings call, Lian gave a timeline that points to a possible 2029 launch for Viking's weight loss candidate.
The Korean drugmaker posted 23.7 billion won in operating profit, crediting Wegovy, which it co-promotes with Novo Nordisk, and the eye drug Eylea.
Loading…